2025年1月14日,“广州市生物医药与健康产业高质量发展交流活动”在广州黄埔区举行,诺诚健华自主研发的奥布替尼成功入选《广州市创新药械目录》并获颁证书。入选是对诺诚健华研发实力与贡献的权威认可,奥布替尼将获广州市全链条重点支持,促进临床应用,满足患者需求。作为国家“重大新药创制”专项成果,奥布替尼靶点精准、个体差异小、无明显脱靶效应,一天一次口服给药方便患者持续治疗,且其获批的四大适应症均已纳入...
Source Link2025年1月14日,“广州市生物医药与健康产业高质量发展交流活动”在广州黄埔区举行,诺诚健华自主研发的奥布替尼成功入选《广州市创新药械目录》并获颁证书。入选是对诺诚健华研发实力与贡献的权威认可,奥布替尼将获广州市全链条重点支持,促进临床应用,满足患者需求。作为国家“重大新药创制”专项成果,奥布替尼靶点精准、个体差异小、无明显脱靶效应,一天一次口服给药方便患者持续治疗,且其获批的四大适应症均已纳入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.